Login to Your Account

CEO: We Want to Digitize Biotech

Zymeworks Inks $187M Merck Deal for Bi-Specific Antibodies

By Jennifer Boggs

Tuesday, August 30, 2011
Privately held Zymeworks Inc. emerged from stealth mode this week, with its first major commercialization deal matching up its bispecific antibody technology with drug development at Merck & Co. Inc. in the areas of oncology and autoimmune diseases.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription